The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists

Novartis halted development of the heart drug pelacarsen after a large clinical trial did not meet its primary endpoint. The drug had been in testing as a potential treatment for heart disease. Novartis did not disclose the specific trial results or timeline for the decision.

Next story